share_log

Even After Rising 23% This Past Week, Dali Pharmaceuticalco.Ltd (SHSE:603963) Shareholders Are Still Down 30% Over the Past Year

Even After Rising 23% This Past Week, Dali Pharmaceuticalco.Ltd (SHSE:603963) Shareholders Are Still Down 30% Over the Past Year

儘管上週上漲了23%,但達利製藥有限公司(上海證券交易所代碼:603963)的股東在過去一年中仍下跌了30%
Simply Wall St ·  2024/03/14 07:59

Dali Pharmaceuticalco.,Ltd (SHSE:603963) shareholders will doubtless be very grateful to see the share price up 54% in the last month. But that doesn't change the fact that the returns over the last year have been less than pleasing. The cold reality is that the stock has dropped 30% in one year, under-performing the market.

達利藥業有限公司, Ltd(上海證券交易所代碼:603963)股東們無疑會非常感激看到上個月股價上漲了54%。但這並不能改變這樣一個事實,即去年的回報並不令人滿意。冷酷的現實是,該股在一年內下跌了30%,表現不及市場。

On a more encouraging note the company has added CN¥371m to its market cap in just the last 7 days, so let's see if we can determine what's driven the one-year loss for shareholders.

更令人鼓舞的是,該公司的市值在過去的7天內就增加了3.71億元人民幣,因此,讓我們看看我們能否確定是什麼導致了股東一年的虧損。

Dali Pharmaceuticalco.Ltd wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

達利製藥有限公司在過去十二個月中沒有盈利,我們不太可能看到其股價與每股收益(EPS)之間存在很強的相關性。可以說,收入是我們的下一個最佳選擇。當一家公司沒有盈利時,我們通常預計收入會有良好的增長。那是因爲如果收入增長可以忽略不計,而且從來沒有盈利,就很難確信一家公司能否實現可持續發展。

Dali Pharmaceuticalco.Ltd's revenue didn't grow at all in the last year. In fact, it fell 26%. That's not what investors generally want to see. The stock price has languished lately, falling 30% in a year. That seems pretty reasonable given the lack of both profits and revenue growth. It's hard to escape the conclusion that buyers must envision either growth down the track, cost cutting, or both.

去年,達利製藥有限公司的收入根本沒有增長。實際上,它下降了26%。這不是投資者普遍希望看到的。股價最近一直低迷,一年內下跌了30%。鑑於利潤和收入增長都不足,這似乎很合理。很難逃避這樣的結論,即買家必須設想要麼實現增長,要麼削減成本,要麼兩者兼而有之。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。

earnings-and-revenue-growth
SHSE:603963 Earnings and Revenue Growth March 13th 2024
SHSE: 603963 2024 年 3 月 13 日的收益和收入增長

Take a more thorough look at Dali Pharmaceuticalco.Ltd's financial health with this free report on its balance sheet.

通過這份免費的資產負債表報告,更全面地了解達利製藥有限公司的財務狀況。

A Different Perspective

不同的視角

We regret to report that Dali Pharmaceuticalco.Ltd shareholders are down 30% for the year. Unfortunately, that's worse than the broader market decline of 11%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.9% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Dali Pharmaceuticalco.Ltd better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Dali Pharmaceuticalco.Ltd you should know about.

我們遺憾地報告,達利製藥有限公司的股東今年下跌了30%。不幸的是,這比整個市場11%的跌幅還要嚴重。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨0.9%的總虧損。我們意識到羅斯柴爾德男爵曾說過,投資者應該 “在街頭流血時買入”,但我們警告說,投資者應首先確保他們購買的是高質量的企業。長期跟蹤股價表現總是很有意思的。但是,爲了更好地了解達利製藥有限公司,我們需要考慮許多其他因素。例如,考慮風險。每家公司都有它們,我們發現了你應該知道的達利製藥有限公司的兩個警告信號。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想與管理層一起購買股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論